|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,198.00 GBX | +0.83% |
|
+17.13% | +20.47% |
| Feb. 06 | European Stocks Track Higher in Friday Trading; Stellantis Tanks on $26.5 Billion Write-Down | MT |
| Feb. 06 | GSK Chair Jonathan Symonds buys GBP53,000 in shares | AN |
Earnings beats, new drug approvals, and focused R&D partnerships bolster confidence in GSK’s 2031 plan, while the CEO appointment of Luke Miels and his ties to AstraZeneca add merger talk to the mix. The target price rises despite HIV patent headwinds.
Published on 12/30/2025 at 01:20 am EST
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Select your edition
All financial news and data tailored to specific country editions
